Neuland Laboratories Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Neuland Laboratories Ltd trades at ₹19,043, in a confirmed uptrend and 12 weeks into that stage. That is +20.4% against its own 200-day average. It sits at 94% of a 52-week range of ₹11,995 to ₹19,506. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 23 straight weeks.

Today the stock is in a confirmed uptrend — week 12 of stage 2, confirmed. At ₹19,043 it trades +20.4% versus its 200-day average and sits at 94% of its 52-week range (₹11,995–₹19,506).

Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +2,984% while the NIFTY 500 moved +276% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 23 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Neuland Laboratories Ltd trades at 67.7× P/E, at the pricey end of its own range (89th percentile). Its long-run median P/E is 34.5×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 67.7× is at the pricey end of its own range (89th percentile), against a long-run median of 34.5× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +39.9% against a +46.3% price move — the price outran earnings, pushing the multiple UP its own range.

The price move, decomposed: over 5y, of the +57.1%/yr price move, ~+38.5%/yr came from earnings growth and ~+18.6 pp from the multiple (expanding); over 10y, of the +35.5%/yr price move, ~+24.8%/yr came from earnings growth and ~+10.7 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.

Stage: Turning around Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Neuland Laboratories Ltd reads as turning around on its fundamental arc. Turning around — profit growth swung from −40.2% at the trough to +39.8%, a 2-quarter improving streak, ROCE lifting at 26.0%. The read is built from 12 quarters across 4 curves, on full evidence.

Why it matters: growth inflections are where re-ratings start — the curves say a turn is forming, so the question becomes whether the next quarters confirm it.

4-Factor Sector Score

76.7/100 — rank 1 of 24 in Pharma - API & CRAMS · 96% evidence confidence

Neuland Laboratories Ltd scores 76.7 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 1. Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence.

The four contributions add to the total exactly: 30.2 + 21.3 + 11.6 + 13.6 = 76.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Neuland Laboratories Ltd reported ₹776 Cr of revenue in the Mar 26 quarter, +136.6% year on year. That is the 3rd straight quarter of year-on-year growth. Over 10 years it has compounded at 14.8% a year. The last full year, FY26, came in at ₹2,023 Cr. The last four reported quarters add to ₹2,023 Cr.

FY26 revenue came in at ₹2,023 Cr (+37.0% on the year), capping 10 years at 14.8% compound. The latest quarter (Mar 26) printed ₹776 Cr, +136.6% year on year — the 3rd consecutive quarter of year-over-year growth.

Pace check: the last four quarters averaged +44.8% growth against the decade's 14.8% — the current year is running faster than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +37.0% over the last 4 quarters against +13.9%/yr over the last 8 — accelerating; TTM profit +39.8% vs +10.3%/yr — accelerating.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Neuland Laboratories Ltd's operating margin is 40.0% in the Mar 26 quarter, +24.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0% to 30.0%. The current quarter is running above every full year in that window.

The latest quarter's operating margin is 40.0%, +24.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–30.0%.

Why the margin moved: operating margin went +24.0 pp year on year while gross margin went +4.0 pp — the gain came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Neuland Laboratories Ltd earned ₹213 Cr of net profit in the Mar 26 quarter, +660.7% year on year. Full-year FY26 profit was ₹364 Cr. The 10-year compound rate is 29.7%. That is 27.4% of the quarter's revenue. The same quarter a year earlier earned ₹28.0 Cr.

Mar 26 profit was ₹213 Cr, +660.7% year on year. On the full year, FY26 printed ₹364 Cr (+40.0%), and the 10-year compound rate is 29.7%.

Why profit moved: revenue contributed +136.6% and the margin +24.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.

Pace comparison, last four quarters: profit +177.3% vs revenue +44.8%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 100% of Neuland Laboratories Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹347 Cr of operating cash against ₹364 Cr of profit. After ₹477 Cr of capital spending, ₹−130 Cr was left as free cash.

FY26: operating cash of ₹347 Cr against reported profit of ₹364 Cr, leaving free cash of ₹−130 Cr after ₹477 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 100% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 100%: the cash cycle stretched 50 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.

Router verdict: the bigger cash user is investment — capital spending ran 3.7× depreciation over three years, so the next section's job is to check what that build-out is buying.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Neuland Laboratories Ltd's cash conversion cycle runs 214 days in FY26, up from 164 days in FY21. Capital spending ran ₹807 Cr over the last 3 years. At FY26 sales of ₹2,023 Cr each day of that cycle holds about ₹5.5 Cr, so roughly ₹1,186 Cr sits inside the business at any moment.

FY26: debtors at 98 days, inventory at 245 days — roughly 8.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 214 days, looser than FY21's 164.

The full loop: cash goes out to suppliers and production on day 0; stock waits 245 days to sell; customers pay about 98 days after that; and suppliers themselves are paid at 129 days — netting out to the 214-day cycle.

In money terms: at FY26 sales of ₹2,023 Cr, each day of the cycle holds about ₹5.5 Cr — so the 214-day loop keeps roughly ₹1,186 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹807 Cr over the last 3 fiscal years against ₹218 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹211 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Neuland Laboratories Ltd earns a ROCE of 26% in FY26. That is up from a trough of 4% in FY18. Return on invested capital clears the cost of that capital by +7.0 percentage points, so growth here adds value rather than only size. The wiring behind it is 18.0% net margin on 0.69× asset turns.

FY26 ROCE is 26%, recovered from a FY18 trough of 4% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY26): 18.0% net margin × 0.69× asset turns × 1.56× balance-sheet leverage ≈ 19.4% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

The capstone test — ROIC − WACC: 19.0% − 12.0% = a +7.0 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.

Neuland Laboratories Ltd carries total debt of ₹301 Cr against shareholder equity of ₹1,874 Cr as of Mar 26, a debt-to-equity of 0.16 — effectively unlevered. On the annual view that ratio went from 0.29 in FY22 to 0.16 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.

Mar 26: total debt of ₹301 Cr against shareholder equity of ₹1,874 Cr — a debt-to-equity of 0.16. On the annual view, debt-to-equity went from 0.29 (FY22) to 0.16 (FY26). The returns on this page are earned, not borrowed.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

Domestic institutions added 10.1 points of Neuland Laboratories Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 16.5% of the company. Foreign institutions moved −4.6 points over the same window, to 21.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Domestic institutions: +10.1 points over 8 quarters to 16.5%; Foreign institutions: −4.6 points over 8 quarters to 21.1%; Promoters: −0.1 points over 8 quarters to 32.6%.

Why the register moved: rotation — foreign institutions −4.6 points against domestic institutions +10.1 points over 8 quarters, with promoters holding steady — one class of institutions handing the register to the other, not a verdict change by the people closest to the numbers.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Neuland Laboratories Ltd: the Z-score reads 12.34. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.

Why it matters: a Z-score of 12.34 sits well clear of the distress zone — the balance sheet is not the risk here.

The safety line in one sentence: the Z-score reads 12.34.

Frequently asked questions